Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

iqvia holdings inc. - IQV

IQV

Close Chg Chg %
194.34 3.24 1.66%

Pre-Market

197.58

+3.24 (1.66%)

Volume: 1.86M

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Trade Now

Company Overview: iqvia holdings inc. - IQV

IQV Key Data

Open

$194.81

 Day Range

191.82 - 197.93

52 Week Range

187.62 - 261.73

 Market Cap

$35.28B

Shares Outstanding

181.50M

 Public Float

180.00M

Beta

1.51

 Rev. Per Employee

N/A

P/E Ratio

25.49

 EPS

$7.72

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.10M

  

IQV Performance

1 Week
 
 2.55%
 
1 Month
 
 -7.93%
 
3 Months
 
 -20.62%
 
1 Year
 
 -6.80%
 
5 Years
 
 37.47%
 

IQV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 25
Full Ratings ➔

About iqvia holdings inc. - IQV

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

IQV At a Glance

IQVIA Holdings, Inc.
2400 Ellis Road
Durham, North Carolina 27703
Phone 1-919-998-2000 Revenue 14.96B
Industry Services to the Health Industry Net Income 1.36B
Sector Health Services 2023 Sales Growth 3.766%
Fiscal Year-end 12 / 2024 Employees 87,000
View SEC Filings

IQV Valuation

P/E Current 25.495
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 31.742
Price to Sales Ratio 2.881
Price to Book Ratio 6.871
Price to Cash Flow Ratio 20.059
Enterprise Value to EBITDA 17.643
Enterprise Value to Sales 3.732
Total Debt to Enterprise Value 0.255

IQV Efficiency

Revenue/Employee 171,988.506
Income Per Employee 15,609.195
Receivables Turnover 4.384
Total Asset Turnover 0.575

IQV Liquidity

Current Ratio 0.862
Quick Ratio 0.862
Cash Ratio 0.23

IQV Profitability

Gross Margin 27.354
Operating Margin 13.634
Pretax Margin 9.751
Net Margin 9.076
Return on Assets 5.221
Return on Equity 22.868
Return on Total Capital 6.676
Return on Invested Capital 7.079

IQV Capital Structure

Total Debt to Total Equity 232.837
Total Debt to Total Capital 69.955
Total Debt to Total Assets 53.338
Long-Term Debt to Equity 219.339
Long-Term Debt to Total Capital 65.90
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Iqvia Holdings Inc. - IQV

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
11.36B 13.88B 14.42B 14.96B
Sales Growth
+2.39% +22.20% +3.90% +3.77%
Cost of Goods Sold (COGS) incl D&A
8.79B 10.50B 10.51B 10.87B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.29B 1.26B 1.13B 1.13B
Depreciation
134.00M 147.00M 160.00M 151.00M
Amortization of Intangibles
1.15B 1.12B 970.00M 974.00M
COGS Growth
+3.35% +19.46% +0.14% +3.41%
Gross Income
2.57B 3.38B 3.91B 4.09B
Gross Income Growth
-0.77% +31.54% +15.55% +4.73%
Gross Profit Margin
+22.64% +24.37% +27.10% +27.35%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.79B 1.96B 2.07B 2.05B
Research & Development
- - - -
-
Other SG&A
1.79B 1.96B 2.07B 2.05B
SGA Growth
+3.17% +9.78% +5.45% -0.87%
Other Operating Expense
- - - -
-
Unusual Expense
46.00M 3.00M 13.00M 32.00M
EBIT after Unusual Expense
736.00M 1.42B 1.82B 2.01B
Non Operating Income/Expense
40.00M 67.00M (67.00M) 170.00M
Non-Operating Interest Income
6.00M 6.00M 13.00M 36.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
403.00M 354.00M 394.00M 719.00M
Interest Expense Growth
-9.84% -12.16% +11.30% +82.49%
Gross Interest Expense
403.00M 354.00M 394.00M 719.00M
Interest Capitalized
- - - -
-
Pretax Income
373.00M 1.13B 1.36B 1.46B
Pretax Income Growth
+5.97% +202.41% +20.83% +7.04%
Pretax Margin
+3.28% +8.13% +9.45% +9.75%
Income Tax
72.00M 163.00M 260.00M 101.00M
Income Tax - Current - Domestic
- 16.00M 24.00M 21.00M
Income Tax - Current - Foreign
244.00M 293.00M 358.00M 349.00M
Income Tax - Deferred - Domestic
(161.00M) (106.00M) (94.00M) (236.00M)
Income Tax - Deferred - Foreign
(11.00M) (40.00M) (28.00M) (33.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
308.00M 971.00M 1.09B 1.36B
Minority Interest Expense
- - 29.00M 5.00M
-
Net Income
279.00M 966.00M 1.09B 1.36B
Net Income Growth
+46.07% +246.24% +12.94% +24.47%
Net Margin Growth
+2.46% +6.96% +7.57% +9.08%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
279.00M 966.00M 1.09B 1.36B
Preferred Dividends
- - - -
-
Net Income Available to Common
279.00M 966.00M 1.09B 1.36B
EPS (Basic)
1.4584 5.047 5.8156 7.3885
EPS (Basic) Growth
+48.97% +246.06% +15.23% +27.05%
Basic Shares Outstanding
191.30M 191.40M 187.60M 183.80M
EPS (Diluted)
1.4308 4.9538 5.724 7.2893
EPS (Diluted) Growth
+49.52% +246.23% +15.55% +27.35%
Diluted Shares Outstanding
195.00M 195.00M 190.60M 186.30M
EBITDA
2.07B 2.68B 2.97B 3.17B
EBITDA Growth
+0.49% +29.63% +10.63% +6.67%
EBITDA Margin
+18.22% +19.32% +20.58% +21.15%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 249.45
Number of Ratings 25 Current Quarters Estimate 3.107
FY Report Date 12 / 2024 Current Year's Estimate 11.118
Last Quarter’s Earnings 2.84 Median PE on CY Estimate N/A
Year Ago Earnings 10.20 Next Fiscal Year Estimate 12.059
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 15 23 23
Mean Estimate 3.11 2.67 11.12 12.06
High Estimates 3.18 2.81 11.20 12.43
Low Estimate 3.02 2.43 10.86 11.52
Coefficient of Variance 1.31 3.82 0.63 1.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 16 17
OVERWEIGHT 3 3 3
HOLD 5 5 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Iqvia Holdings Inc. - IQV

Date Name Shares Transaction Value
Jul 23, 2024 John G. Danhakl Director 1,988 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2024 Leslie Wims Morris Director 2,423 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2024 Colleen A. Goggins Director 3,790 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2024 James A. Fasano Director 1,518 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 John G. Danhakl Director 1,723 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Sheila A. Stamps Director 1,047 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 James A. Fasano Director 1,363 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 John M. Leonard Director 13,783 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Carol J. Burt Director 1,047 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Leslie Wims Morris Director 2,300 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Colleen A. Goggins Director 3,634 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 Colleen A. Goggins Director 3,481 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 John P. Connaughton Director 1,047 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 10, 2024 John G. Danhakl Director 1,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2024 W. Richard Staub See Remarks 15,945 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $249.08 per share 3,971,580.60
Mar 5, 2024 Ari Bousbib See Remarks; Director 828,430 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.16 per share 53,980,498.80
Mar 5, 2024 Ari Bousbib See Remarks; Director 812,169 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $250.05 per share 203,082,858.45
Mar 5, 2024 Ari Bousbib See Remarks; Director 796,752 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $251.03 per share 200,008,654.56
Mar 5, 2024 Ari Bousbib See Remarks; Director 785,583 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $249.97 per share 196,372,182.51
Mar 5, 2024 W. Richard Staub See Remarks 18,013 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $248.33 per share 4,473,168.29

Iqvia Holdings Inc. in the News